Macrophage polarization contributes to distinct human pathologies. In tumors, a polarized M2 phenotype called tumor-associated macrophages (TAMs) are associated with promotion of invasion and angiogenesis. In cancer cells, vacuolar ATPase (V-ATPase), a multi-subunit enzyme, is expressed on the plasma/vesicular membranes and critically influences the metastatic behavior. In addition, the soluble, cleaved N-terminal domain of a2 isoform of V-ATPase (a2NTD) is associated with in vitro induction of pro-tumorigenic properties in monocytes. This activity of a2 isoform of V-ATPase (a2V) caused us to investigate its role in cancer progression through the evaluation of the immunomodulatory properties of a2NTD. Here, we present direct evidence that surface expression of V-ATPase is associated with macrophage polarization in tumor tissue. Macrophages from BALB/c mice (peritoneal/ bone marrow derived) were stimulated with recombinant a2NTD in both ex vivo and in vivo systems and evaluated for TAM characteristics. a2V was highly expressed in tumor tissues (breast and skin) as well as on the surface of tumor cell lines. The a2NTD-stimulated macrophages (a2MF) acquired TAM phenotype, which was characterized by elevated expression of mannose receptor-1, Arginase-1, interleukin-10 and transforming growth factor-b. a2MF also exhibited increased production of other tumorigenic factors including matrix metalloproteinase-9 and vascular endothelial growth factor. Further, a2MF were cocultured with mouse B-16F0 melanoma cells for their functional characterization. The coculture of these a2MF subsequently increased the invasion and angiogenesis of less invasive B-16F0 cells. When cocultured with naive T cells, a2MF significantly inhibited T-cell activation. The present data establish the role of V-ATPase in modulating a macrophage phenotype towards TAMs through the action of a2NTD, suggesting it to be a potential therapeutic target in cancer.
INTRODUCTION
The modulation of the cellular microenvironment towards favorable conditions is essential for tumor growth and progression. For this purpose, tumor cells produce various factors, which interact with the neighboring cells and modulate their functions for their own advantage. Vacuolar ATPases (V-ATPases) are multisubunit enzymes present on the various endomembranes of cells and are required for many functions and cytosolic pH regulation. Tumor cells express V-ATPases on their surface to maintain a lowpH extracellular environment, and are required for growth and survival of these cells. 1 Besides pH regulation, V-ATPases are also involved in drug resistance, invasion and metastasis of tumor cells. [1] [2] [3] Previous studies have shown that the a2 isoform of the 'a' subunit of V-ATPase (a2V) has a role in cancer-related inflammation and maintenance of pregnancy. [4] [5] [6] [7] The soluble N-terminus domain of a2V (a2NTD) is cleaved from the a2 subunit, secreted through micro-vesicles from cancer cells, and stimulates monocytes to produce interleukin (IL)-1b and IL-10, which are important for cancer related inflammation. 6, 8 Macrophages can change their functional profiles according to environmental stimuli and can be classified as M1 and M2 macrophages. 9, 10 M1 macrophages are induced by lipopolysaccharides and interferon-g, and have antitumor activities. They produce pro-inflammatory cytokines including tumor necrosis factor-a, IL-1, IL-6, IL-12 or IL-23. In contrast, IL-4/ IL-13 stimulation induces M2 macrophages, which are involved in the response to parasites, tissue remodeling, angiogenesis and tumor progression and in producing anti-inflammatory cytokines IL-10 and transforming growth factor-b. In addition, the M2 subtype is characterized by the expression of Arginase-1, CD206 (mannose receptor) and CD204 (scavenger receptor A). 11 Among the cells in leukocyte infiltrates of tumors, macrophages are a major component and referred to as tumor-associated macrophages (TAMs). TAMs have been proposed to exhibit many similarities in terms of gene expression and function with alternatively activated M2 macrophages. 12 TAMs produce a host of growth factors that affect tumor-cell proliferation, angiogenesis and degradation of the extracellular matrix. These factors include epidermal growth factor, members of the fibroblast growth factor family, transforming growth factor-b, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs) and several distinct chemokines. 13 In this study, we established an association between V-ATPase and host immune responses in cancer. We demonstrate that V-ATPases are present in abundance during cancer and the a2V subunit is highly expressed on the surface of tumor cells. Murine macrophages were stimulated with a2NTD, referred to as a2MF, and cocultivation of these a2MF with tumor cells induced invasion and angiogenesis of tumor cells. Further, a2MF were able to inhibit T-cell activation when cocultured with naive T cells. To our knowledge this is the first study establishing the direct involvement of V-ATPases in modulating host immune responses, through the signal of a2NTD, in tumor progression.
RESULTS AND DISCUSSION
In comparison with other subunits of V-ATPase, the role of a2 has been less investigated in association with cancer. Here, we examined the expression of a2V in two different tumor tissues (breast tumors and melanomas) as well as on tumor cell lines. Both of the tumor tissues were highly positive for a2V staining compared with their respective normal tissues (Figure 1a) . In breast tumor tissue, most of the a2V-positive cells were located in the lumen, where hyperplasia exists. By immunoblotting, the elevated protein expression of both a2V and a2NTD was observed in tumor tissue compared with control ( Figure 1b) . In cell lines, a2V was highly expressed on the surface of all cell lines with varying intensity, which was correlated with their reported invasive potential (Figure 1c ). 4T1 cells showed the highest a2V expression, whereas, B-16F0 showed the lowest a2V expression (Figure 1d) . The above results suggest that the elevated expression of a2V in cancer cells might contribute to both tumor growth and aggressiveness.
To determine the role of the soluble fragment of a2V (a2NTD) in cancer, we investigated the effect of a2NTD stimulation on the induction of macrophage phenotype (M1or M2) in ex vivo and in vivo systems. In both systems, mRNA expression of M2 markers was significantly upregulated with a2NTD treatment compared with untreated cells. No significant difference was observed between the groups for M1 marker gene expression (Figures 2a  and d) . Further, mRNA expression was validated at the protein level by flow cytometry and immunofluorescence assay. In both ex vivo and in vivo flow cytometric analyses, elevated numbers of F4/80 þ CD206 þ (M2) cells were observed (Figures 2b and e) and the difference was significant with a2NTD treatment compared with controls (Figures 2c and f) . Interestingly, more M2 cells were observed in in vivo compared with ex vivo a2NTD treatment, suggesting a possible influence of a2NTD on other cells, which further contributed to increased M2-polarized macrophage levels. However, no significant difference was observed for the various treatment groups with regard to the number of F4/80 þ CD11c þ (M1) cells. Immunofluorescence assay also confirmed an increase in the number of M2 cells after in vivo a2NTD stimulation ( Figure 2i ). As TAMs are functionally M2 macrophages, 12 the above results strongly suggest that a2NTD modulates the macrophage phenotype towards TAMs. Many observations indicate that TAM express several pro-tumoral proteins, including those that promote angiogenesis, matrix remodeling and the suppression of adaptive immunity by producing factors like chemokines and cytokines (CCL17, CCL18, CCL22, IL-10), Arginase-1, MMPs, and VEGF. 13, 14 The After determining that a2NTD stimulation polarized macrophages towards TAMs, we further investigated whether a2MF have functional properties of TAMs. TAMs contribute to tumor 14 To determine whether a2MF can stimulate the angiogenic properties of B-16F0 cells, an in vitro angiogenesis assay was performed using mouse C166 umbilical vein endothelial cells. 15 The supernatants derived from B-16 cells that had been cocultured with a2MF showed an increase in the numbers of tube-like structures of C166 compared with C166 only or non-cocultured B-16 cells (both Po0.05; Figures 4c and d) . TAM plays a major role in suppression of T-cell activation in tumors. 12 To investigate the immunosuppressive properties of a2MF, naive T cells were cocultured with a2MF, and T-cell activation (CD25 expression) and proliferation were measured. Coculture with a2MF significantly inhibited CD25 expression (Figures 4e and f) or T-cell proliferation (Figure 4g ) in comparison to coculture with untreated MF (Po0.05).
A number of studies have shown that V-ATPases are expressed on the surface of tumor cells in a tissue-specific manner and, particularly, a3 and a4 isoforms of the 'a' subunit are important for pH regulation and metastasis of tumor cells. 1, [16] [17] [18] Further, the inhibition of these subunits at the transcript level has a significant impact on related functions. 18, 19 In our study, the presence of a2V on tumor tissues or cancer cells indicates its potential role in cancer, which has not been investigated well before. Here, the elevated expression of TAM markers, after a2NTD stimulation, suggested the immunomodulatory capacity of a2NTD on macrophages. In tumor cells, we have shown that a2NTD is cleaved from a2V subunit and secreted in microvesicles from these cells. Also, the level of a2NTD correlated with the expression of a2V. 6 This observation supported the possibility that tumor cells express high levels of a2V on their surface to modulate the phenotype of resident macrophages toward TAMs through the action of a2NTD. TAMs produce multiple factors like MMPs to degrade the extracellular matrix, VEGF to enhance angiogenesis at the tumor site, and several chemokines to recruit Th2 and Treg cells to the tumor site; all of them further contribute to tumor a2V-ATPase promotes tumor-associated macrophages GK Katara et al survival and growth. 13 Our investigation of tumorigenic factors confirmed that a2MF secreted these factors, confirming that a2MF are TAMs. It has been established that TAM makes a significant contribution to tumor-associated immunosuppression through the secretion of factors such as CCL17, CCL22, transforming growth factor-b, IL-10 and Arginase-1.
14 In our study, the levels of all of these factors were elevated after a2NTD treatment and a2MF successfully inhibited T-cell activation when cocultured with naive T-cells. We speculate that a2MF mediates suppression of T-cell activation through these factors. The enhancement in the invasive as well as angiogenic potential of tumor cells and suppression of T-cell activation after cocultivation with a2MF confirmed that a2MF have a similar impact on cancer cells as TAMs and are phenotypically and functionally similar to TAMs.
In summary, this study reveals that V-ATPase can promote tumor survival and growth. We have identified the following evidence to support this conclusion. First, the analytical results of cancer tissues and cells point out that there is an overexpression of a2V on tumors. Second, in response to a2NTD, macrophages expressed and secreted distinct TAM associated molecules. Third, a2MF directly contributes to T-cell suppression, and the invasion and angiogenesis of cancer cells. These findings demonstrate a crucial role of V-ATPase in the progression of cancer through the action of a2NTD. A drug-mediated inhibition of V-ATPase has been used before for therapeutic purpose in cancer, but development of drug resistance is a major obstacle in disease cure. 20, 21 siRNAbased targeting of V-ATPase has shown promising results for controlling drug resistance and metastasis in a human xenograft cancer model. 22, 23 Here, we suggest that a2V may represent an effective and potentially selective cancer gene for molecular targeted therapies to control tumor growth and survival by involving the host immune system.
MATERIALS AND METHODS

Cells and tissue samples
Mouse malignant melanoma B16-F0, B16-F10, mouse breast cancer 4T1 cells and mouse embryonic endothelial cells C166 (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM) or DMEM-Ham's F12 or RPMI 1640 (Invitrogen, Grand Island, NY, USA) media with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine (Sigma, St Louis, MO, USA). BALB/c mice, 6-8 weeks old, were purchased from Jackson Labs (Bar Harbor, ME, USA) and were maintained at the Rosalind Franklin University Animal Care Facility. All experiments were conducted with institutional animal care and use committee approval. The peritoneal cells were harvested by injecting 7 ml of ice-cold phosphatebuffered saline and peritoneal macrophages (PMF) were purified by isolating adherent cells and checked by flow cytometry for purity, yielding 80-85% F4/80 þ cells. For bone marrow-derived macrophages (BMF), femurs were obtained from mice and flushed with RPMI 1640 to extrude the bone marrow. The bone marrow was homogenized and cells were cultured in RPMI 1640 with macrophage colony-stimulating factor (50 ng/ ml) (R&D Systems, Minneapolis, MN, USA) for 15 days. Cell culture medium was subsequently changed every 3 days with fresh medium. For immunohistochemistry and western blot, human tumor or normal frozen tissue sections and protein lysates were procured from Biochain, Newark, CA, USA.
Gelatin zymography and ELISA
The concentrated serum-free media from a2MF was mixed with sample buffer and applied directly, without prior heating or reduction, to 10% zymogram gels containing 1 mg/ml gelatin. After electrophoresis, the SDS was removed from the gel by incubating in 2.5% (v/v) Triton X-100 (Sigma) for 30 min. The gels were then incubated at 37 1C overnight in development buffer (50 mmol/l Tris-HCl, pH 7.6, containing 0.2 M NaCl, 5 mmol/l CaCl 2 ) for 24 h at 37 1C. Gels were then stained with 0.2% Coomassie blue. White bands representing gelatinase activity were photographed. The same serum-free supernatants were subjected to ELISA for IL-10, VEGF-A and MMP-9 (R&D Systems) in accordance with the manufacturer's instructions.
Arginase activity assay
Arginase activity was measured in untreated or a2MF cell lysates by using arginase assay kit, Bioassay (US Biologicals, Swampscott, MA, USA). Briefly, cells were lysed with lysis buffer (0.1% Triton X-100, 100 mg/ml pepstatin, 100 mg/ml aprotinin and 100 mg/ml antipain). A 10-ml sample volume was subjected to arginase assay in accordance with the manufacturer's instructions. Data are given as milliunits of arginase/10 6 cells, where 1 U of arginase is defined as the amount of enzyme that catalyzes the formation of 1 mg of urea/min. ) were resuspended in 200 ml of serum-free DMEM and added to the upper inserts. DMEM (500 ml) with 10% FCS was added to the lower chamber. After 24 h, invaded cells were used for fluorometric analysis as per the manufacturer's instructions.
In vitro angiogenesis assay C166 (1 Â 10 4 cells in 100 ml/well) were seeded into a BD Matrigel (BD Biosciences, San Jose, CA, USA) coated (50 ml/well) 48-well plate and 100 ml of 10-fold concentrated conditioned media from B-16F0 cells, previously cocultured or non-cocultured with a2MF, was added and incubated for 48 h at 37 1C. Tube-like structures of C166 formed at 48 h were counted under a microscope. a2V-ATPase promotes tumor-associated macrophages GK Katara et al
Suppression of T-cell activation
Mouse peritoneal macrophages were isolated and stimulated with a2NTD (500 ng/ml) or interferon-g (20 ng/ml) or IL-4 (20 ng/ml). After 48 h, an equal number of splenocytes was added and cocultured for 48 h in flatbottom 48-well plates. These cocultures were stimulated with anti-CD3F and anti-CD28 for 24 h. Expression of CD25 (eBiosciences, San Diego, CA, USA) (a T-cell activation marker) was analyzed on CD3 þ cells by flow cytometry. 24 A similar set of cells was used to analyze T-cell proliferation by methylthiazol tetrazolium assay (Promega, Madison, WI, USA) as described before.
